Search Results - yihong+ye

5 Results

Sort By:

COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)

The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS...

Published: 7/25/2024 | Inventor(s): Qi Zhang, Wei Zheng, Catherine Chen, Yihong Ye

Keywords(s): COVID-19, DB4BXX, ENTRY, HEPARAN, option, Sulfate-dependent, Targeting, therapeutic, viral

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics

A method to label heparan sulfate proteoglycan in the plasma membrane of mammalian cells

Heparan sulfate proteoglycan (HSPG) is a group of lipid-anchored proteoglycans, engaged in a variety of key biological functions on cell surface. HSPG-mediated endocytosis of neurotoxic protein aggregates has been linked to aging related neurodegenerative diseases. Labeling HSPG is a promising technique to trace cell profile in cell research, monitor...

Published: 7/25/2024 | Inventor(s): Qi Zhang, Yihong Ye

Keywords(s): Cells, HEPARAN, Label, MAMMALIAN, MEMBRANE, Method, PLASMA, PROTEOGLYCAN, R1XXXX, SULFATE, XCXXXX

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials

Bag6 Polyclonal Antibodies That Recognize Human Bag6 Protein

Bag6 (BCL2 associated athanogene 6) is a multifunctional chaperone involved in tail anchored protein biogenesis, endoplasmic reticulum-associated protein degradation, and degradation of mislocalized membrane proteins. It is the central component of a stable three chaperone complex that also contains two cofactors-Ubl4A and Trc35. This complex acts...

Published: 7/25/2024 | Inventor(s): Yihong Ye

Keywords(s): antibodies, Bag6, CC1AXX, DD1XXX, Human, Polyconal, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RECOGNIZE, That, WIXXXX, YGXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Research Materials, TherapeuticArea > Infectious Disease

Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders

The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may...

Published: 7/25/2024 | Inventor(s): Yihong Ye, William Trenkle, Adrian Wiestner

Keywords(s): anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology

Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers

The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...

Published: 7/25/2024 | Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner

Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology